Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Alessandro Mantovani(Azienda Ospedaliera Universitaria Integrata Verona), Giovanni Targher(Ospedale Sacro Cuore Don Calabria), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Eleonora Scorletti(University of Pennsylvania), Christopher D. Byrne(Southampton General Hospital)
Cited by 140
Related Papers
Role of leptin in the neuroendocrine response to fasting
|Nature|1996|3.1k
NAFLD: A multisystem disease
|Journal of Hepatology|2015|3.1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Adverse metabolic and cardiovascular consequences of circadian misalignment
|Proceedings of the National Academy of Sciences|2009|2.3k